{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:56:54Z","timestamp":1772769414090,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.japh.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T12:14:00Z","timestamp":1706012040000},"page":"377-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Addressing buprenorphine supply barriers: A guidance commentary"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1682-3431","authenticated-orcid":false,"given":"Jordan W.","family":"Khail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-2515","authenticated-orcid":false,"given":"Smita","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-3288","authenticated-orcid":false,"given":"Henry N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.japh.2024.01.013_bib1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.japh.2023.04.016","article-title":"The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice","volume":"63","author":"Varisco","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"8","key":"10.1016\/j.japh.2024.01.013_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing isn't enough - pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2024.01.013_bib3","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend. Rep"},{"issue":"4","key":"10.1016\/j.japh.2024.01.013_bib4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.japh.2023.04.029","article-title":"Addressing buprenorphine bottlenecks in the context of MAT Act implementation: a shared responsibility","volume":"63","author":"Ostrach","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"8","key":"10.1016\/j.japh.2024.01.013_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.japh.2024.01.013_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2024.01.013_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"Red flags' and 'red tape': telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.japh.2024.01.013_bib11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jsat.2014.07.015","article-title":"Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants","volume":"48","author":"Fox","year":"2015","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"14","key":"10.1016\/j.japh.2024.01.013_bib12","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","article-title":"Patient barriers and facilitators to medications for opioid use disorder in primary care","volume":"54","author":"Tofighi","year":"2019","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.japh.2024.01.013_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Subst. Abuse Rehabil"},{"issue":"4","key":"10.1016\/j.japh.2024.01.013_bib15","first-page":"272","article-title":"DEA disconnect leads to buprenorphine bottlenecks","volume":"15","author":"Ostrach","year":"2021","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.japh.2024.01.013_bib18","article-title":"Factors in rural community buprenorphine dispensing","volume":"9","author":"Major","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"1","key":"10.1016\/j.japh.2024.01.013_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.japh.2024.01.013_bib20","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.japh.2022.04.019","article-title":"North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:52:33Z","timestamp":1761544353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1544319124000207"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.01.013","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing buprenorphine supply barriers: A guidance commentary","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}